INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
← catalyst calendarNCT07224321 · readout ≤ 224 d
Sponsored by Mannkind Corporation (industry) · MNKD — their whole pipeline →. With Jaeb Center for Health Research.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-04 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 1 Diabetes Mellitus
Interventions
- Drug: Technosphere Insulin — also filed as Afrezza
- Drug: Technosphere Insulin — also filed as Afrezza
- Drug: Basal insulin
Primary outcome
what the primary-completion date above is the date OFPercentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70%
measured 13 weeks
Permalink · MNKD's whole pipeline · Catalyst calendar · Every registered study · What changed